European approval of Palforzia for desensitising children and adolescents to peanut allergy

Approval in patients aged 4 to 17 years was based on the PALISADE and ARTEMIS phase III clinical trials which demonstrated that Palforzia (Arachis hypogaea oral capsules) led to an increase in the amount of peanut protein tolerated in subjects with peanut allergy, vs placebo.

Source:

PharmaTimes